Incidence and Outcomes of Cystoid Macular Edema after Descemet Membrane Endothelial Keratoplasty (DMEK) and DMEK Combined with Cataract Surgery

Autor: Simon P. Holland, Alfonso Iovieno, Sonia N. Yeung, Steven S. Bae, Martin McCarthy, Albert T Covello, Rusty Ritenour, Geoffrey Ching
Rok vydání: 2020
Předmět:
Male
Visual acuity
Triamcinolone acetonide
genetic structures
medicine.medical_treatment
Anti-Inflammatory Agents
Benzeneacetamides
Visual Acuity
Glaucoma
Administration
Ophthalmic
Nepafenac
Triamcinolone Acetonide
Corneal Diseases
0302 clinical medicine
Lens Implantation
Intraocular
Risk Factors
Phenylacetates
Aged
80 and over
Incidence
Anti-Inflammatory Agents
Non-Steroidal
Middle Aged
Sensory Systems
Treatment Outcome
Drug Therapy
Combination
Female
Epiretinal membrane
medicine.symptom
Uveitis
medicine.drug
medicine.medical_specialty
Prednisolone
education
Cataract Extraction
Slit Lamp Microscopy
Cataract
Macular Edema
03 medical and health sciences
Cellular and Molecular Neuroscience
Ophthalmology
medicine
Humans
Macular edema
Aged
Retrospective Studies
business.industry
Cataract surgery
medicine.disease
eye diseases
030221 ophthalmology & optometry
Ophthalmic Solutions
business
030217 neurology & neurosurgery
Descemet Stripping Endothelial Keratoplasty
Zdroj: Current eye research. 46(5)
ISSN: 1460-2202
Popis: Purpose To investigate the incidence and outcomes of cystoid macular edema (CME) after Descemet membrane endothelial keratoplasty (DMEK) alone and DMEK combined with cataract surgery (DMEK triple). Materials and methods A retrospective chart review was performed for patients who underwent DMEK and DMEK triple between January 2014 and March 2018 at two tertiary hospitals. Patients with minimum of 6 months of follow-up were included. Logistic regression analysis was used to identify potential risk factors for CME including gender, age, glaucoma, uveitis, epiretinal membrane, diabetes mellitus, iridotomy, and rebubbling. Results 09 eyes of 193 patients who underwent DMEK (124 eyes) and DMEK triple (85 eyes) were included. The 6-month incidence of CME was 3.8% (8/209) for all cases, 2.4% (2/85) for DMEK triple, and 4.8% (6/124) for DMEK alone. CME was treated with topical prednisolone acetate 1% and nepafenac four times daily, and/or periocular triamcinolone acetonide, with resolution in all cases. On average, CME was detected 8.9 ± 2.1 weeks postoperatively, with a mean time to resolution of 4.1 ± 1.7 months. The 6-month best-corrected distance visual acuity of eyes that developed CME was not significantly different compared to eyes that did not develop CME (0.17 ± 0.15 logMAR vs. 0.23 ± 0.27 logMAR; p = .76). On logistic regression analysis, no risk factors for developing CME were identified. Conclusions The incidence of CME after DMEK was low and not associated with decreased long-term visual acuity. Most cases of CME occurred between 1 and 3 months postoperatively. Predictive factors for CME after DMEK require further study.
Databáze: OpenAIRE
Externí odkaz: